Please ensure Javascript is enabled for purposes of website accessibility

Why Facebook Has a Health Team Working On COVID Issues (Including Vaccines)

By Corinne Cardina - Feb 27, 2021 at 6:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Facebook's Head of Health KX Jin explains why he's focused on providing users with accurate and local vaccine information.

With more than 2.6 billion daily users, it's no secret that Facebook (FB 0.81%) reaches a lot of people around the world across Facebook, Messenger, Instagram, and WhatsApp. Even before the pandemic, there's been a surge in demand for health information online. Building on its COVID-19 information center, the tech stock recently announced a big push to provide authoritative information about coronavirus vaccines. This new campaign will connect users with localized vaccination information, remove more vaccine misinformation from its platforms, and donate $120 million in ad credits to health agencies around the world. 

Corinne Cardina, Fool.com's healthcare and cannabis bureau chief, got the chance to speak with Facebook's Head of Health KX Jin on Feb. 10 about Facebook's plan to increase trust and confidence in COVID-19 vaccines. Here's what he said about his job leading health efforts at the social media giant.

 

 

Corinne Cardina: Hi, everybody. I am Corinne Cardina, I'm the Bureau Chief of Healthcare and Cannabis on Fool.com. I'm so thrilled to welcome KX Jin who is Head of Health at Facebook. KX and I are going to talk about some big news regarding Facebook's efforts to help with COVID-19 recovery and vaccination. Hi there, KX, and welcome to Fool Live. How are you today?

KX Jin: Doing well. Thank you for having me.

Cardina: Excellent. I would love to start by sharing your background with our audience. You've had a long career at Facebook, starting out as a software engineer and working as a product lead on many different projects across the company. I imagine you know Facebook inside out, and of course, now you are head of health. Could you tell me briefly about how your different experiences at Facebook prepared you for this role and are there people with health or medical expertise on your team?

Jin: I've been at Facebook a little over 14 years now, working across roles and teams. I started as an engineer two weeks before we launched News Feed, and then I spent a long time in various engineering and products roles. About two years ago after seeing how people were using Facebook tools and products to connect around health and for health-related support, we decided to create a dedicated team to support this area more deliberately as part of our social impact work. Health really affects everyone. Adjusting people's health needs requires a team to incorporate a broad set of perspectives. The individual themselves, but also friends and family, caregivers, clinicians, and other healthcare experts. Our team has people with all of these perspectives on it. We also work very closely in partnership with outside health experts and organization. In my time at Facebook, I've had the privilege to go to a lot of these teams in different areas over the last decade. I'm tremendously grateful now to have the opportunity to do that in health.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Meta Platforms, Inc. Stock Quote
Meta Platforms, Inc.
FB
$193.18 (0.81%) $1.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.